Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Cathie Wood is buying shares of Beam Therapeutics even though they are down. Stocks can fall for all sorts of reasons that aren't relevant in the long term.

This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It.

Pacific Biosciences of California

Spotify

Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of California, a genetic sequencing company, multiple times this week.

Cathie Wood's Buying These 3 Stocks Hand Over Fist

First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease Models

Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation

BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States

Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences:

Beam Therapeutics to Participate in Upcoming September Investor Conferences

COMPASS Pathways

908 Devices

Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices.

3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street

Axsome Therapeutics

Brookfield Renewable Partners

Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics' base-editing technology could be a huge moneymaker over time.

Got $200? 3 Growth Stocks to Buy That Could Double Your Money

Beam Therapeutics Inc. (BEAM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.02 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer.

Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May investor conferences:

Beam Therapeutics to Participate in Upcoming May Investor Conferences

Intellia Therapeutics

Teladoc

Cathie Wood's Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.

Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Wednesday, May 17, 2023, at 11:00 a.m. ET in NYC.

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.01 per share a year ago.

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

Block

Cerus

Ginkgo Bioworks Holdings

UiPath

Roku

Shopify

Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.

7 Best Cathie Wood Stocks for Your May 2023 Buy List

CRISPR Therapeutics

Twist Bioscience Corp

Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.

3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers

Editas Medicine

Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it.

The 3 Most Promising Gene Editing Stocks to Buy in 2023

Canaan Inc.

Murphy USA

Heading toward the midway point of the year, the unique dynamics associated with the post-pandemic new normal sets the stage for certain stocks to watch. That is, brewing fundamental and technical factors appear to favor fortuitously structured or positioned enterprises.

3 Stocks to Watch in April: Is it Time to Buy?

Apple

Fiverr

Jumia

Microsoft

Novo Nordisk

A the market returns it's time to look for the best growth stocks to buy.  successful investing strategy partially requires an ability to predict the future.

7 Top Growth Stocks to Buy for the Next Decade

ARK Innovation ETF

Coinbase

Verve Therapeutics

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global

Legend Biotech

Roivant Sciences Ltd

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Guggenheim 2023 Genomic Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:10 a.m. ET in NYC.

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO). Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities. Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam's research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

News for Beam Therapeutics Stock (BEAM)